Design and synthesis of novel HDAC6 inhibitor dimer as HDAC6 degrader for cancer treatment by palladium catalysed dimerisation.
The enigmatic histone deacetylase 6 (HDAC6) is one of a kind among its family.
APA
Lin C, Hsu JL, et al. (2025). Design and synthesis of novel HDAC6 inhibitor dimer as HDAC6 degrader for cancer treatment by palladium catalysed dimerisation.. Journal of enzyme inhibition and medicinal chemistry, 40(1), 2468355. https://doi.org/10.1080/14756366.2025.2468355
MLA
Lin C, et al.. "Design and synthesis of novel HDAC6 inhibitor dimer as HDAC6 degrader for cancer treatment by palladium catalysed dimerisation.." Journal of enzyme inhibition and medicinal chemistry, vol. 40, no. 1, 2025, pp. 2468355.
PMID
40013582
Abstract
The enigmatic histone deacetylase 6 (HDAC6) is one of a kind among its family. Recent reports revealed that HDAC6 CD1 exhibits E3 ligase activity. Inspired by these researches, we attempted to develop drugs targeting HDAC6 novel mechanism. Herein, we report a palladium catalysed transformation and purification method for hydroxamic acid dimers, and series of HDAC6 inhibitor-based dimer showing outstanding biological activities and capability of inducing auto-degradation. Our proof-of-concept was highlighted with 2-amino benzamide-based HDAC6 inhibitor dimers that exhibit great HDAC6 inhibition activity (3.9-15.4 nM), good HDAC1/6 selectivity (95-577), and excellent cytotoxicity against human hormone-resistant prostate cancer (HRPC) PC-3 and non-small cell lung cancer (NSCLC) A549 cell lines (5.9-11.3 and 6.6-17.9 μM, respectively) while simultaneously inducing HDAC6 degradation. These dimers not only induce apoptosis and autophagy but also interfere with kinetochore attachment by the detection of BUBR1 phosphorylation at S670.
MeSH Terms
Humans; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Antineoplastic Agents; Drug Screening Assays, Antitumor; Molecular Structure; Structure-Activity Relationship; Drug Design; Dose-Response Relationship, Drug; Dimerization; Palladium; Cell Proliferation; Apoptosis; Hydroxamic Acids; Catalysis; Cell Line, Tumor
같은 제1저자의 인용 많은 논문 (5)
- Defining the heterogeneous molecular landscape of lung cancer cell responses to epigenetic inhibition.
- Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer.
- Genetic and Molecular Mechanisms Linking Breast Cancer to Meningioma Risk: Roles of EXO1, BRCA2, and ESR1.
- The vessels encapsulating tumor clusters (VETC) pattern is a negative predictor for first-line immune checkpoint inhibitors alone in unresectable hepatocellular carcinoma.
- Exploring targeted therapies against RFPL3 for non-small cell lung cancer with lymph node metastasis.